CD44 and cancer: Survivin‐2B‐specific cytotoxic T lymphocytes were produced and evaluated for their ability to target CD44+ (cancer stem‐like cells) and CD44− cells (non‐cancer stem‐like cells), respectively, from oral cancer cell lines (HSC‐2 and HSC‐3, respectively).